Castle Biosciences develops and commercializes molecular diagnostic tests that help clinicians assess risk and guide treatment decisions in oncology and related fields. Its best-known DecisionDx assays focus on skin cancers such as cutaneous melanoma, as well as other conditions where gene-expression profiling can refine prognosis. Tests are ordered by specialists and run in the company’s laboratories, placing it at the intersection of dermatology, oncology, and precision diagnostics.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 88 | — | -25.9 | — |
| Q2 2025 | 86.2 | — | 4.5 | — |
| Q3 2025 | 83 | — | -0.5 | — |
| Q4 2025 | 87 | — | -2.3 | — |
| Q1 2026 | 83.7 | -4.9% | -14.5 | — |
| Q2 2026 | 103.5 | 20.1% | -2.1 | -145.5% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Evolution Metals & Technologies Corp. (EMAT), CeriBell, Inc. (CBLL), Sigma Lithium Corporation (SGML), NB Bancorp, Inc. (NBBK), Seaport Therapeutics, Inc. (SPTX), Upbound Group, Inc. (UPBD)